Mast Cell –Targeting Therapies in Mast Cell Activation Syndromes

AbstractPurpose of ReviewProvide an overview of the expanding landscape of mast cell (MC) –targeting treatments in mast cell activation syndromes (MCAS).Recent FindingsTyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation. Avapritinib has been recently approved by the FDA for the treatment of indolent systemic mastocytosis (ISM). Targeting activation pathways and inhibitory receptors is a promising therapeutic frontier. Recently, the anti Siglec-8 antibody lirentelimab showed promising results in ISM.SummaryMCAS is a heterogeneous disorder demanding a personalized therapeutic approach and, especially when presenting as anaphylaxis, has not been formally captured as outcome in prospective clinical trials with TKI. Long-term safety of TKI needs to be addressed. New drugs under investigation in diseases  in which non-neoplastic MCs play a pivotal role can provide important inputs to identify new efficient and safe treatments for MCAS.
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research